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ABSTRACT 
The recombinant expression of heterologous proteins in microorganisms, 
such Escherichia coli, is often Improved by producing the protein of interest 
Iranslationally linked to another, often unrelated, protein giving to a "fusion 
protein" construct. For many applications it is desirable or imperative to separate 
the extraneous material from the protein of interest. An increasingly popular 
approach to this task is the use of site-specific endoproteases 10 excise the 
protein product. A number of commerCially available site-specific proteases 
exist, but many are not capable of generating an authentic N-terminus for the 
product, display unsatisfactory specificity leading to adventitious cleavage of the 
product, or they are unsuitable for an industrial process, 
Mutants of the serine protease a-Lytic protease have been shown to 
satisfy many of the cflteria for an industrially sUitable protease and have been 
applied to the cleavage of some important fusion proteins used in the production 
of members of the Insulin-like Growth Factor (IGF) family Lacking from these 
examples, however, is any viable proteolytic solution for the liberation of human 
IGF-I from fusion proteins. This has been primarily attributed to the Proline 
bearing N-terminal tripeptide sequence of this protein, which is known to be 
refractory to the activity of many site-specific proteases 
It has been suggested that in the generation of two combinatorial mutant 
libraries of a-Lytic protease, the preference for amino acids C-terminal to the 
cleavage site may have been altered, It is the purpose of this work to first 
determine if such an alteration has been made in any of the mutants so as to 
allow cleavage immediately before the N-terminus of human IGF-I, and then to 
task the lead mutant(s) to the cleavage of the full-Iengttl fusion protein All 
members of the two mutant libraries were cultured and their activity confirmed 
and quantified against a generic \-casein substrate in a high-throughput assay 
A second high-throughput technique was then employed to query the mutant 
proteases for their ability to catalyse proteolysis at the required sequence in a 
peptide model, Finding that many mutants appeared successful at this task, the 
findings were verified on a longer peptide model of the cleavage site. 
Initially the yields achieved by cleavage of the full-length IGF-I fusion 
protein by a lead candidate mutant a-Lytic protease were not sufficient to satisfy 
the requirements of an industrial process, despite alteratlcn of the reaction 
conditions. However, the insight gained from these reactions could be applied to 
the redesign of the protein structure around the intended site of cleavage, 
Significantly improving site-specific proteolYSis. The IGF-I generated by this 
cleavage has been shown to be bloequivalent to commercial reference standard 
to cultured mammalian cells and the yield of this process Is approximately 5-fold 
improved over the existing cleavage system. 
